Google Updates Policy to Allow CBD Advertising in Select Markets

Jan.11.2023
Google Updates Policy to Allow CBD Advertising in Select Markets
Google allows ads for marijuana and topical CBD products in California, Colorado and Puerto Rico, and FDA-approved drugs.

Google has updated its policies on "dangerous products and services, as well as healthcare and drugs," allowing advertisements for marijuana and topical CBD products to be promoted in California, Colorado, and Puerto Rico in the United States.


Google did not provide a clear explanation for why it is limiting ads in these three distinct markets.


The company stated that CBD advertisements for entertainment products are still subject to limitations, including "supplements, food additives and inhalants." Additionally, according to policy revisions, header ads on YouTube (owned by Google) appear at the top of the main homepage on all devices and do not apply to marijuana and CBD products.


Google also stated that drugs approved by the Food and Drug Administration (FDA) can now be advertised in these jurisdictions. This rule change will only benefit one manufacturer, Jazz Pharmaceuticals, whose high-CBD Epidiolex is the only product of its kind that the agency has approved to date. Epidiolex is used to treat severe seizures in children and was approved by the FDA in 2020.


These changes were announced at the end of the year and will take effect on January 20th. Advertisers can start applying for Google certification from that date and the application form will be released.


Google has announced that it has signed a contract with LegitScript, an internet and payment compliance company based in Portland, Oregon. LegitScript provides certification in high-risk industries and serves as a credential exchange for determining product advertising eligibility. Only products certified by LegitScript are permitted to be promoted on the Google platform.


According to Google, individuals seeking to advertise on the platform must provide their product samples or THC tests, and provide third-party analysis certificates to LegitScript for verification.


In an industry where contaminated, substandard, or illegal products are still prevalent, it is more important than ever to assure consumers that the CBD products they are purchasing have undergone proper scrutiny," said Scott Ross, CEO of LegitScript.


This internet giant appears to be unnerved by the prospect of continuing to use CBD products internally. Such products have received warnings from the FDA, as various studies have shown contamination by solvents and heavy metals among other impurities. Delta-8 THC derived from cannabis produced via synthetic processes has been implicated in the death of a child in Virginia last year.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Smoore International (6969.HK) released its 2025 results on March 17 and held an investor presentation on the morning of March 18. In morning trade on March 18, the company’s shares fell more than 16% intraday, hitting a low of HK$9.94.
Mar.18 by 2FIRSTS.ai
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan Named 2026 SRNT Fellow for Contributions to Nicotine Research
Andy Tan, Ph.D., has been named a 2026 Fellow of the Society for Research on Nicotine and Tobacco (SRNT), an international professional association dedicated to advancing nicotine and tobacco research. Fellows are selected for outstanding research contributions as well as leadership, mentoring, and policy engagement within the field.
Feb.23
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s ANSES warns vaping carries health risks, urges limiting e-cigarette use to smoking cessation
France’s National Agency for Food, Environmental and Occupational Health & Safety (ANSES) says vaping poses health risks because users inhale toxic or harmful substances, even if e-cigarettes are generally considered less harmful than cigarettes.
Feb.04 by 2FIRSTS.ai
China Tobacco Jiangsu Industrial Patent Points to 3D-Printed Nicotine Oral Products
China Tobacco Jiangsu Industrial Patent Points to 3D-Printed Nicotine Oral Products
Jiangsu China Tobacco Industrial Co., Ltd. has disclosed a patent describing a nicotine oral formulation produced using 3D printing technology. The invention enables a three-stage nicotine release system—rapid onset, sustained delivery and long-term release—through a layered structure with varying porosity. The technology reflects growing experimentation within China Tobacco’s research system around precision nicotine delivery for modern oral products.
Mar.09
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24